Nuclear Receptors as Potential Therapeutic Targets for Age-Related Macular Degeneration

Author(s):  
Goldis Malek
2012 ◽  
Vol 4 (17) ◽  
pp. 2153-2161 ◽  
Author(s):  
Kai Kaarniranta ◽  
Anu Kauppinen ◽  
Janusz Blasiak ◽  
Antero Salminen

Cells ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 1102 ◽  
Author(s):  
Sonali Nashine ◽  
M. Cristina Kenney

Substantive evidence demonstrates the contribution of mitochondrial dysfunction in the etiology and pathogenesis of Age-related Macular Degeneration (AMD). Recently, extensive characterization of Mitochondrial-Derived Peptides (MDPs) has revealed their cytoprotective role in several diseases, including AMD. Here we summarize the varied effects of MDPs on cellular and mitochondrial health, which establish the merit of MDPs as therapeutic targets for AMD. We argue that further research to delve into the mechanisms of action and delivery of MDPs may advance the field of AMD therapy.


2013 ◽  
Vol 54 (14) ◽  
pp. ORSF68 ◽  
Author(s):  
Catherine Bowes Rickman ◽  
Sina Farsiu ◽  
Cynthia A. Toth ◽  
Mikael Klingeborn

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Makoto Ishikawa ◽  
Daisuke Jin ◽  
Yu Sawada ◽  
Sanae Abe ◽  
Takeshi Yoshitomi

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population, and the prevalence of the disease increases exponentially with every decade after the age of 50 years. While VEGF inhibitors are promising drugs for treating patients with ocular neovascularization, there are limitations to their potential for improving vision in AMD patients. Thus, future therapies are required to have the potential to improve visual outcomes. This paper will summarize the future strategies and therapeutic targets that are aimed at enhancing the efficacy and duration of effect of antiangiogenic strategies.


2012 ◽  
Vol 4 (3) ◽  
pp. 277-287 ◽  
Author(s):  
Shusheng Wang ◽  
Kyle M Koster ◽  
Yuguang He ◽  
Qinbo Zhou

Sign in / Sign up

Export Citation Format

Share Document